Drug Trial Radar · NCT06501443
LATAM LOWERS LDL-C
Last checked: Nov 20, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
520
Planned (sponsor's estimate)
Start
Feb 11, 2025
Primary completion
Nov 27, 2026
Study completion Nov 29, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, patient-level 1:1 randomized clinical trial in a multi-country study aiming to evaluate the real-world impact of inclisiran + Usual Care (UC) vs UC alone on LDL-C lowering, patient-reported outcomes, and healthcare resource utilization in an in-hospital population of patients, admitted during the acute setting, stabilized and before discharge, following an acute cardiovascular event.
Conditions
- Hypercholesterolaemia
Interventions
Usual careDrug
Treatment after acute event approved in the country where patient is based. It may include educational intervention according to each country guidelines
KJX839Drug
Inclisiran in solution for subcutaneous injection on day 1, day 90, and day 270
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in LDL-C from baseline to 330 daysTime frame: Baseline and Day 330
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Corrientes, Argentina · Recruiting
Novartis Investigative Site
Campina Gde Do Sul, Brazil · Recruiting
Novartis Investigative Site
Salvador, Brazil · Recruiting
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil · Recruiting
Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil · Recruiting
Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil · Recruiting
Novartis Investigative Site
Campo Largo, Paraná, Brazil · Recruiting
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Novartis Investigative Site
Blumenau, Santa Catarina, Brazil · Withdrawn
Novartis Investigative Site
São José, Santa Catarina, Brazil · Recruiting
Novartis Investigative Site
São José, São Paulo, Brazil · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.